Type 2 responses determine skin rash during recombinant interleukin-2 therapy
The skin is the organ most often affected by adverse drug reactions. Although these cutaneous adverse drug reactions (CADRs) often are mild, they represent a major burden for patients. One of the drugs inducing CADRs is aldesleukin, a recombinant interleukin-2 (recIL-2) originally approved to treat...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Taylor & Francis Group
2024-12-01
|
| Colección: | Journal of Immunotoxicology |
| Materias: | |
| Acceso en línea: | https://www.tandfonline.com/doi/10.1080/1547691X.2024.2343359 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|